Abstract
Erlotinib is the first EGFR TKI to be approved in Czech Republic for use in advanced NSCLC. This analysis presented examines data of all pts treated in Czech republic between 12/2005 and 12/2010.
Data of all 1735 patients were summarised and retrospective analyses were carried out to determine if any associations were seen between specific characteristics and either mPFS or mOS.
Of the 1735 pts with advanced NSCLC 35,6% were female and 64,4% male, 21,6% non-smokers, 39,5% former smokers and 38,9% current smokers. Median age was 65 years. Erlotinib was used as 1st line therapy in 14,4%, as 2nd line in 47,3% and as 3rd line in 38,3% pts. PS 0 was in 7,6%, PS 1 in 56,3%, PS 2 in 33,5% and PS 3 in 2,6% pts. Adenocarcinoma was confirmed in 45,9%, squamous-cell carcinoma in 39,2%, large–cell carcinoma in 4,0% and non specified carcinoma in 9,4% pts. CR was confirmed in 0,6%, PR in 123 7,1% pts, SD in 44,1% of pts; 23% of pts progressed and 25,2% pts were not evaluated. Skin toxicity was in 56,7%. Median survival (95% CI) was 7,5 months, PFS (95% CI) was 2,9 months. The differences between groups of pts according to PS (0+1 vs. 2+3) were statistically significant (p < 0,001). The best median survival (17,6 month) was in the group of pts with PS 0. Statistically significantly longer (p < 0,001) was mOS and mPFS survival in patients with skin toxicity, in female pts, in non-smokers and in pts with adenocarcinoma.
Erlotinib in this non-selected group of pts with advanced NCCLC was well tolerated and the results from Czech Republic are better then the data from BR.21 study and comparable with the results of TRUST.
- © 2011 ERS